SCHEMBL9908375

SCHEMBL9908375

CC(C)CCCN1C(=O)CCC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
HTT P42858 2/20 0.46
POLB P06746 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 1/20 0.37
SORT1 Q99523 1/20 0.36
PIK3CD O00329 2/20 0.35
CYP1A2 P05177 1/20 0.35
HTR1A P08908 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTR7 P34969 1/20 0.35
MAPT P10636 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17574699 0.86 ALDH1A1 (0.53) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL19161741 0.82 POLB (0.37) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL24937778 0.80 POLB (0.40) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL888672 0.78 MEN1 (0.50) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL8829446 0.78 FAAH (0.53) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL19162068 0.76 TSHR (0.43) ALDH1A1SMN1; SMN2SORT1
SCHEMBL19161166 0.76 PLA2G7 (0.44) ALDH1A1HTTMEN1KMT2ASORT1
SCHEMBL1982535 0.76 MGLL (0.52) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL8629340 0.76 MGLL (0.52) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL8829438 0.76 MGLL (0.52) ALDH1A1HTTPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230235365-A1 ENGINEERED RETRONS AND METHODS OF USE RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-07-27 US disclosed
US-20230235365-A1 ENGINEERED RETRONS AND METHODS OF USE RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-07-27 US disclosed
US-20230130155-A1 MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2023-04-27 US disclosed
US-20230130155-A1 MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2023-04-27 US disclosed
US-11220476-B2 Compounds and compositions for intracellular delivery of therapeutic agents MODERNATX, INC. (US) 2022-01-11 US disclosed
WO-2021022173-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLS MODERNATX, INC. (US) 2021-02-04 WO disclosed
US-20200123100-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2020-04-23 US disclosed
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS MODERNATX, INC. 2019-10-17 US disclosed
US-10442756-B2 Compounds and compositions for intracellular delivery of therapeutic agents MODERNATX, INC. (US) 2019-10-15 US disclosed
US-10392341-B2 Compounds and compositions for intracellular delivery of therapeutic agents MODERNATX, INC. (US) 2019-08-27 US disclosed
US-20150253673-A1 PATTERN FORMING METHOD, RESIST PATTERN FORMED BY THE METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2015-09-10 US disclosed
US-8357682-B2 Gamma secretase modulators MERCK SHARP & DOHME LLC 2013-01-22 US disclosed
US-8357682-B2 Gamma secretase modulators MERCK SHARP & DOHME LLC 2013-01-22 US disclosed
US-8198016-B2 Patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20110263529-A1 GAMMA SECRETASE MODULATORS MERCK SHARP & DOHME CORP. 2011-10-27 US disclosed
US-20110263529-A1 GAMMA SECRETASE MODULATORS MERCK SHARP & DOHME CORP. 2011-10-27 US disclosed
US-20100247514-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2010-09-30 US disclosed
US-20100247514-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2010-09-30 US disclosed
US-20090286188-A1 Patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-11-19 US disclosed
US-7163778-B2 Anti-reflection film material and a substrate having an anti-reflection film and a method for forming a pattern SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392341-B2 Compounds and compositions for intracellular delivery of therapeutic agents LNPK, PLTP, PLIN3 ALDH1A1 4530/4885HTT 2525/4885POLB 2763/4885
US-20100247514-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 ALDH1A1 3991/4885HTT 502/4885POLB 1904/4885
US-10442756-B2 Compounds and compositions for intracellular delivery of therapeutic agents LNPK, PLTP, PLIN3 ALDH1A1 4530/4885HTT 2525/4885POLB 2763/4885
US-11220476-B2 Compounds and compositions for intracellular delivery of therapeutic agents LNPK, PLTP, PLIN3 ALDH1A1 4530/4885HTT 2525/4885POLB 2763/4885
US-20200123100-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS LNPK, PLTP, PLIN3 ALDH1A1 4530/4885HTT 2525/4885POLB 2763/4885
US-20110263529-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 ALDH1A1 3991/4885HTT 502/4885POLB 1904/4885
US-20230130155-A1 MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF HMOX1, CD209, HMOX2 ALDH1A1 115/4885HTT 1271/4885POLB 3174/4885
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS LCP2, CD14, MYD88 ALDH1A1 4722/4885HTT 2816/4885POLB 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.